PI3K/AKT/mTOR

role in breast cancer progression, drug resistance, and treatment

Angel Guerrero-Zotano, Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.

Original languageEnglish (US)
Pages (from-to)515-524
Number of pages10
JournalCancer and Metastasis Reviews
Volume35
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

1-Phosphatidylinositol 4-Kinase
Drug Resistance
Breast Neoplasms
Neoplasms
Therapeutics
Drug Delivery Systems
Oncogenes
Carcinogenesis
Clinical Trials
Mutation
Pharmaceutical Preparations

Keywords

  • AKT
  • Breast cancer
  • mTOR
  • PI3K

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

PI3K/AKT/mTOR : role in breast cancer progression, drug resistance, and treatment. / Guerrero-Zotano, Angel; Mayer, Ingrid A.; Arteaga, Carlos L.

In: Cancer and Metastasis Reviews, Vol. 35, No. 4, 01.12.2016, p. 515-524.

Research output: Contribution to journalArticle

@article{6f8a6773c6544008bbd8246aeba4fbb3,
title = "PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment",
abstract = "Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.",
keywords = "AKT, Breast cancer, mTOR, PI3K",
author = "Angel Guerrero-Zotano and Mayer, {Ingrid A.} and Arteaga, {Carlos L.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s10555-016-9637-x",
language = "English (US)",
volume = "35",
pages = "515--524",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - PI3K/AKT/mTOR

T2 - role in breast cancer progression, drug resistance, and treatment

AU - Guerrero-Zotano, Angel

AU - Mayer, Ingrid A.

AU - Arteaga, Carlos L.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.

AB - Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.

KW - AKT

KW - Breast cancer

KW - mTOR

KW - PI3K

UR - http://www.scopus.com/inward/record.url?scp=84997831559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997831559&partnerID=8YFLogxK

U2 - 10.1007/s10555-016-9637-x

DO - 10.1007/s10555-016-9637-x

M3 - Article

VL - 35

SP - 515

EP - 524

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 4

ER -